|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
GlaxoSmithKline |
| Information provided by: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT00043927 |
Purpose
This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.
| Condition | Intervention | Phase |
|
Small Cell Lung Cancer |
Drug: topotecan/cisplatin Drug: etoposide/cisplatin |
Phase III |
| MedlinePlus related topics: | Cancer Lung Cancer |
| ChemIDplus related topics: | Etoposide Cisplatin Topotecan hydrochloride Topotecan Etoposide phosphate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin as Treatment for Chemotherapy-Naive Patients With Extensive Disease-Small Cell Lung Cancer. |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations![]() |
Show 178 Study Locations |
| GlaxoSmithKline |
| Study Director: | GSK Clinical Trial, MD | GlaxoSmithKline |
More Information
| Study ID Numbers: | 104864-A/389 |
| First Received: | August 14, 2002 |
| Last Updated: | March 6, 2006 |
| ClinicalTrials.gov Identifier: | NCT00043927 |
| Health Authority: | United States: Food and Drug Administration; United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|
|
|
|
|